Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$2.12
+3.9%		$2.76
$1.99
▼
$6.44
$396.82M0.163.46 million shs3.47 million shs
Amgen Inc. stock logo
AMGN
Amgen
$478.48
+3.7%		$421.56
$302.13
▼
$482.48
$249.37B0.432.64 million shs4.62 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,418.14
+0.6%		$1,207.75
$850.51
▼
$1,449.68
$1.33T0.42.66 million shs3.63 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$400.43
+1.0%		$492.40
$353.54
▼
$615.00
$9.16B-0.98396,056 shs2.31 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.21
+5.0%		$40.84
$35.12
▼
$64.16
$179.45B0.710.24 million shs25.98 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$110.68
+28.0%		$96.29
$74.50
▼
$122.20
$5.92B2.171.02 million shs5.48 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.97
+7.2%		$30.10
$23.82
▼
$43.15
$3.33B0.794.81 million shs4.38 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+3.92%+0.95%-20.60%-29.57%-43.62%
Amgen Inc. stock logo
AMGN
Amgen
+3.73%+5.90%+18.74%+18.19%+61.27%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.67%+9.99%+23.83%+18.98%+56.44%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.04%-7.09%-18.88%-21.54%-9.94%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+5.14%+10.39%+12.41%-8.05%-12.56%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+28.04%+20.34%+19.72%-1.27%+5.42%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+7.21%+10.29%-4.47%-16.01%-19.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$2.12
+3.9%		$2.76
$1.99
▼
$6.44
$396.82M0.163.46 million shs3.47 million shs
Amgen Inc. stock logo
AMGN
Amgen
$478.48
+3.7%		$421.56
$302.13
▼
$482.48
$249.37B0.432.64 million shs4.62 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,418.14
+0.6%		$1,207.75
$850.51
▼
$1,449.68
$1.33T0.42.66 million shs3.63 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$400.43
+1.0%		$492.40
$353.54
▼
$615.00
$9.16B-0.98396,056 shs2.31 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.21
+5.0%		$40.84
$35.12
▼
$64.16
$179.45B0.710.24 million shs25.98 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$110.68
+28.0%		$96.29
$74.50
▼
$122.20
$5.92B2.171.02 million shs5.48 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$27.97
+7.2%		$30.10
$23.82
▼
$43.15
$3.33B0.794.81 million shs4.38 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+3.92%+0.95%-20.60%-29.57%-43.62%
Amgen Inc. stock logo
AMGN
Amgen
+3.73%+5.90%+18.74%+18.19%+61.27%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.67%+9.99%+23.83%+18.98%+56.44%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.04%-7.09%-18.88%-21.54%-9.94%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+5.14%+10.39%+12.41%-8.05%-12.56%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+28.04%+20.34%+19.72%-1.27%+5.42%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+7.21%+10.29%-4.47%-16.01%-19.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.70
Moderate Buy$14.33576.10% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.31
Hold$413.38-13.61% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.86
Moderate Buy$1,404.14-0.99% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.76
Moderate Buy$706.8776.53% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4440.83% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.77
Moderate Buy$141.9428.25% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.79
Moderate Buy$93.36233.80% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$452.00 ➝ $531.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform$400.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$430.00 ➝ $470.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$384.00 ➝ $440.00
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$430.00 ➝ $460.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
11/4/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$470.00 ➝ $530.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetSector Outperform$500.00 ➝ $530.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$405.00 ➝ $465.00
(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K10,309.56N/AN/A$1.99 per share1.07
Amgen Inc. stock logo
AMGN
Amgen
$36.75B7.04$35.08 per share13.64$16.08 per share29.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.47$25.29 per share56.07$42.81 per share33.13
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M9.65N/AN/A$26.54 per share15.09
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.03$4.92 per share8.57$6.58 per share6.41
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M39.97N/AN/A$2.08 per share53.21
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$0.78N/AN/AN/AN/A-31.41%-26.96%11/5/2026 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0919.9019.443.3824.14%128.15%13.58%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8144.1128.341.7631.90%86.76%22.03%N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A75.55N/A-10.89%-27.93%-12.50%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0910.0012.341.3635.36%58.61%20.91%11/4/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-69.03%-159.32%-42.76%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$5.40N/AN/AN/AN/A-117.35%-88.87%N/A

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.14N/AN/AN/A$0.00 millionN/A
11/4/2026Q3 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.7310$0.8770+$0.1460$0.57$11.07 billion$12.00 billion
11/3/2026Q3 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.79$6.45+$0.66$7.08$10.07 billion$10.37 billion
11/3/2026Q3 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$1.09$1.83+$2.92$1.83$404.17 million$431.27 million
11/3/2026Q3 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.7097-$0.61+$0.0997-$0.61$85.57 million$92.13 million
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.06-$1.55-$0.49-$1.55N/AN/A
8/12/2026Q2 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.1355-$0.12+$0.0155-$0.12$0.00 millionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Amgen Inc. stock logo
AMGN
Amgen
$10.082.11%+8.27%62.65%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.49%+15.18%22.46%11 Years
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.94%+21.74%20.05%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.25%11/20/202611/20/202612/11/2026
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.54%11/13/202611/13/202612/10/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.07
26.78
26.78
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.43
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
57194.52 million191.41 millionOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41468.53 million64.49 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65127.52 million120.76 millionOptionable

Recent News About These Companies

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
November 4 at 7:15 AM  |  fool.comhttps://www.fool.com/investing/2026/11/04/viking-therapeutics-trades-xx-below-its-own-35-off/
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3 at 9:22 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-participate-upcoming-investor-213000179.html
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3 at 4:30 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302928444.html
Viking Therapeutics (NASDAQ:VKTX) Stock Price Target Raised at Canaccord Genuity Group
November 2 at 8:17 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-viking-therapeutics-nasdaq-vktx-stock-price-target-raised-at-canaccord-genuity-group-2026-11-02/
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
November 2 at 7:22 AM  |  fool.comhttps://www.fool.com/investing/2026/11/02/ubs-just-initiated-coverage-of-viking-therapeutics/
HC Wainwright Issues Pessimistic Estimate for VKTX Earnings
November 2 at 1:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172612
HC Wainwright Has Negative Estimate for VKTX FY2026 Earnings
November 2 at 1:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-has-negative-estimate-for-vktx-fy2026-earnings-2026-11-02/
Viking Therapeutics Bets Big on VK2735 in Earnings Call
October 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/8565720/viking-therapeutics-bets-big-on-vk2735-in-earnings-call/
Viking Therapeutics: A Strong Injection, A Scaled-Back Pill
October 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4960571-viking-therapeutics-a-strong-injection-a-scaled-back-pill
Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Genmab (GMAB)
October 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GMAB/pressreleases/8553573/analysts-conflicted-on-these-healthcare-names-viking-therapeutics-vktx-and-genmab-gmab/
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
October 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3019949/vktx-is-a-2029-launch-for-its-obesity-drug-within-reach?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-3019949
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
October 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3019520/brokers-suggest-investing-in-viking-therapeutics-vktx-read-this-before-placing-a-bet?cid=cs-stocknewsapi-ft-fundamental_analysis|average_broker_rating-3019520
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
October 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/brokers-suggest-investing-viking-therapeutics-123002124.html
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
October 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4959640-viking-therapeutics-q3-update-why-you-cant-discount-this-glp-1-player-yet
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
October 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3018977/vktx-q3-earnings-miss-estimates-amid-rising-clinical-expenses?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-3018977
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
October 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3018436/vktx-q3-earnings-call-highlights-obesity-pipeline-progress?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-3018436
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
October 29, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/29/eli-lilly-jumps-8-as-strong-quarter-lifts-revenue-outlook-novo-nordisk-ticks-up-viking-therapeutics-eases/?utm_source=snapi
Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?
October 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-posted-wider-081818204.html
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock
October 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4959186-viking-therapeutics-successful-maintenance-readout-couldnt-save-stock
Viking Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
October 29, 2026  |  marketscreener.comM
Viking (VKTX) Q3 2026 Earnings Call Transcript
October 29, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/10/28/viking-vktx-q3-2026-earnings-call-transcript/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Multi-monitor trading desk displaying stock price charts, Q3 earnings data with EPS and revenue figures, and market data in an office.
Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
By Thomas Hughes | October 11, 2026
AbbVie logo over a laboratory scene with vials, a pipette, and a DNA helix illustration.
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
By Thomas Hughes | November 2, 2026
A Boeing commercial aircraft parked on a tarmac at sunset, with the Boeing logo overlaid on the sky.
Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
By Dan Schmidt | October 28, 2026
Microsoft logo displayed over an illuminated glass office building at dusk, reflected in a water feature.
Microsoft Is Almost Back to $555—Now the Hard Part Begins
By Chris Markoch | October 9, 2026
Comfort Systems USA logo over rooftop HVAC units and piping at a data center facility during sunset.
Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
By Dan Schmidt | October 26, 2026
Altimmune stock logo

Altimmune NASDAQ:ALT

$2.12 +0.08 (+3.92%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$2.12 0.00 (-0.19%)
As of 11/4/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Amgen stock logo

Amgen NASDAQ:AMGN

$478.48 +17.22 (+3.73%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$477.92 -0.56 (-0.12%)
As of 11/4/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,418.14 +8.76 (+0.62%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$1,419.88 +1.74 (+0.12%)
As of 11/4/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$400.43 +4.11 (+1.04%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$401.48 +1.05 (+0.26%)
As of 11/4/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$42.21 +2.02 (+5.02%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$41.80 -0.41 (-0.96%)
As of 11/4/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$110.68 +24.24 (+28.04%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$109.12 -1.56 (-1.41%)
As of 11/4/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$27.97 +1.88 (+7.21%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$27.99 +0.02 (+0.06%)
As of 11/4/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas